GLP1R and obesity due to melanocortin 4 receptor deficiency: Since the safety profile of GLP1 analog drugs has been proven in the treatment of type 2 diabetes and obesity in human patients, its effectiveness in treating other diseases or conditions such as AUD will be highly favorable in new drug development.